Keurig Dr Pepper Inc.
KDPKeurig Dr Pepper Inc.'s three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
The sharpest disagreement: annual EPS moved +45.7% against a −6.7% price move — the market has not yet caught up with the delivery.
The price is topping out (16 weeks in) while the P/E sits at the 43rd percentile of its own 4-year range. Underneath, the last four quarters read deteriorating — profit −48.1% year on year, and 97% of the last 3 years' profit arrived as cash. What settles it: whether the price catches up with earnings that have already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Keurig Dr Pepper Inc. trades at $31.1, losing momentum at the top and 16 weeks into that stage. That is +8.5% against its own 200-day average. It sits at 59% of a 52-week range of $25 to $35. On relative strength it has been ahead of the S&P 500 on a trailing-13-week view for 2 straight weeks.
Today the stock is losing momentum at the top — week 16 of stage 3. At $31.1 it trades +8.5% versus its 200-day average and sits at 59% of its 52-week range ($25–$35).
Against the market, two honest reads. Cumulative: over the last 8.1 years the stock moved +28% while the S&P 500 moved +176% — behind the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 2 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.
Keurig Dr Pepper Inc. trades at 23.1× P/E, mid-range by its own standards (43rd percentile). Its long-run median P/E is 23.8×, measured across 4.3 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 23.1× is mid-range by its own standards (43rd percentile), against a long-run median of 23.8× measured over 4.3 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved +45.7% against a −6.7% price move — earnings outran the price, pushing the multiple DOWN its own range.
The price move, decomposed: over 3y, of the −2.5%/yr price move, ~+5.8%/yr came from earnings growth and ~−8.3 pp from the multiple (compressing). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: Improving Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Keurig Dr Pepper Inc. reads as improving on its fundamental arc. Improving — profit growth bottomed 3 quarters ago at −29.6% and has held its recovery at +20.4%, ROCE holding at 6.6%. The read is built from 12 quarters across 4 curves, on full evidence.
Why it matters: a sustained climb off the trough is the setup this page is built to catch — the question moves to what you pay for it.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +8.1% | +5.7% | — | — |
| Profit | +44.4% | +13.0% | — | — |
| EPS | +45.7% | +14.8% | — | — |
| Stock price | −6.7% | −2.5% | −1.9% | — |
4-Factor Sector Score
50.5/100 — rank 5 of 13 in Beverages - Non-Alcoholic · 66% evidence confidence
Keurig Dr Pepper Inc. scores 50.5 out of 100 against the 13 companies it is compared with in Beverages - Non-Alcoholic, ranking 5. Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity.
The four contributions add to the total exactly: 14.4 + 9.8 + 14.2 + 12.1 = 50.5. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Keurig Dr Pepper Inc. reported $4.0 B of revenue in the Mar 26 quarter, +9.6% year on year. That is the 12th straight quarter of year-on-year growth. Over 4 years it has compounded at 7.0% a year. The last full year, FY25, came in at $16.6 B. The last four reported quarters add to $16.9 B.
FY25 revenue came in at $16.6 B (+8.1% on the year), capping 4 years at 7.0% compound. The latest quarter (Mar 26) printed $4.0 B, +9.6% year on year — the 12th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +9.3% growth against the decade's 7.0% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +9.3% over the last 4 quarters against +6.5%/yr over the last 8 — stabilising; TTM profit +20.4% vs −8.0%/yr — accelerating.
Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Keurig Dr Pepper Inc.'s operating margin is 19.1% in the Mar 26 quarter, −2.9 percentage points against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 16.9% to 22.8%. The current quarter sits inside that band.
The latest quarter's operating margin is 19.1%, −2.9 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 16.9%–22.8%.
🚨 Why the margin moved: operating margin went −2.9 pp year on year while gross margin went −2.0 pp — the loss came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Keurig Dr Pepper Inc. earned $0.3 B of net profit in the Mar 26 quarter, −48.1% year on year. Full-year FY25 profit was $2.1 B. That is 6.8% of the quarter's revenue. The same quarter a year earlier earned $0.5 B. 1 of the last 12 reported quarters were loss-making.
Mar 26 profit was $0.3 B, −48.1% year on year. On the full year, FY25 printed $2.1 B (+44.4%).
🚨 Why profit moved: revenue contributed +9.6% and the margin −2.9 pp — the quarter was revenue-led despite a thinner margin.
Pace comparison, last four quarters: profit −11.9% vs revenue +9.3%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 97% of Keurig Dr Pepper Inc.'s reported profit arrived as operating cash — the cash follows the profit. In FY25 that was $2.0 B of operating cash against $2.1 B of profit. After $0.5 B of capital spending, $1.5 B was left as free cash.
FY25: operating cash of $2.0 B against reported profit of $2.1 B, leaving free cash of $1.5 B after $0.5 B of capital spending. Across the last 3 fiscal years the conversion rate is 97% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why: conversion is measured cleanly, but the working-capital day-counts behind it sit below what we hold — the move is shown without inventing its driver.
Router verdict: the visible cash user is investment — the next section checks what the spending is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Keurig Dr Pepper Inc. does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $1.0 B over the last 3 years. Averaged over those years that is 2.0% of FY25 revenue a year.
Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.
On the investment side: capital spending of $1.0 B over the last 3 fiscal years.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.
Keurig Dr Pepper Inc. earns a ROE of 8% in FY25. That is up from a trough of 0% in FY21. Return on invested capital clears the cost of that capital by +0.6 percentage points, so growth here adds value rather than only size. The wiring behind it is 12.5% net margin on 0.30× asset turns.
FY25 ROE is 8%, recovered from a FY21 trough of 0% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY25): 12.5% net margin × 0.30× asset turns × 2.17× balance-sheet leverage ≈ 8.1% on equity. Margin does its share; leverage is a meaningful part of the equation.
The capstone test — ROIC − WACC: 5.4% − 4.8% = a +0.6 pp spread. The 4.8% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. Positive but thin — value creation with little room for error.
Dividend A dividend is cash paid out per share. Dividend per share is the declared amount for the period; the trailing twelve-month total is the four most recent quarters added together.
Keurig Dr Pepper Inc. paid $0.92 per share over the last four reported quarters, up 7.0% on a year ago. The most recent declaration was $0.23 for Mar 26. Against the current price of $31.1 that is a trailing yield of 2.96%, measured on dividends already paid rather than on a forecast.
Keurig Dr Pepper Inc. paid $0.92 per share across the last four reported quarters, most recently $0.23 for Mar 26. That is up 7.0% against the same quarter a year earlier. Against the current price of $31.1 the trailing twelve months work out to 2.96% — trailing dividends measured against today's price, not a forward estimate.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Keurig Dr Pepper Inc. carries total debt of $25.7 B against shareholder equity of $29.2 B as of Mar 26, a debt-to-equity of 0.88. On the annual view that ratio went from 0.48 in FY21 to 0.63 in FY25. Read the returns elsewhere on this page with that leverage in mind.
Mar 26: total debt of $25.7 B against shareholder equity of $29.2 B — a debt-to-equity of 0.88. On the annual view, debt-to-equity went from 0.48 (FY21) to 0.63 (FY25). Read the returns on this page with that leverage in mind.
Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.
4.7% of Keurig Dr Pepper Inc.'s tradable float is currently sold short — some money is positioned against it. At typical trading volumes those positions would take about 3.6 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.
The latest reading: 4.7% of the float is sold short, and at typical trading volumes it would take about 3.6 days to buy those positions back. Some money is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.
Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Keurig Dr Pepper Inc.: the Z-score reads 1.34. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits inside the distress zone. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
🚨 Why it matters: a Z-score of 1.34 is inside the distress zone — the balance sheet is a real risk, not a detail.
The safety line in one sentence: the Z-score reads 1.34.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Monster Beverage CorporationMNST | 66.6/100Favorable setup66% evidence | FADING | 21.4/35 Revenue 18% · PAT 34.5% · OPM change 0.3 pp 53% evidence | 15.8/25 ROCE 9.1% · OPM 31% 57% evidence | 11.9/20 P/E 35× · PEG 0.97 65% evidence | 17.5/20 RS sector 14.8% · RS bench 8.3% · 1Y 45.6%9 of 12 weeks ahead 100% evidence |
| Exact sum: 21.4 + 15.8 + 11.9 + 17.5 = 66.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 2The Vita Coco Company, Inc.COCO | 63.2/100Thin evidence · provisional56% evidence | FADING | 22.6/35 Revenue — · PAT — · OPM change 4 pp 39% evidence | 18.1/25 ROCE 17.4% · OPM 18.7% 76% evidence | 9.4/20 P/E 36.5× · PEG — 15% evidence | 13.1/20 RS sector 12.2% · RS bench 5.9% · 1Y 98.5%10 of 12 weeks ahead 100% evidence |
| Exact sum: 22.6 + 18.1 + 9.4 + 13.1 = 63.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 3The Coca-Cola CompanyKO | 59.9/100Thin evidence · provisional56% evidence | TURNING | 18.8/35 Revenue — · PAT — · OPM change 0.9 pp 39% evidence | 14.4/25 ROCE 5.7% · OPM 35% 76% evidence | 10.0/20 P/E 25.3× · PEG — 15% evidence | 16.7/20 RS sector 10.1% · RS bench 3.8% · 1Y 23.1%2 of 12 weeks ahead 100% evidence |
| Exact sum: 18.8 + 14.4 + 10 + 16.7 = 59.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 4PepsiCo, Inc.PEP | 55.3/100Mixed-positive evidence81% evidence | BASING | 24.4/35 Revenue 5.6% · PAT 38.3% · OPM change 8.7 pp 83% evidence | 11.8/25 ROCE 5.5% · OPM 16.6% 76% evidence | 15.9/20 P/E 18.9× · PEG 0.48 65% evidence | 3.2/20 RS sector -11% · RS bench -16.3% · 1Y -4.2%0 of 12 weeks ahead 100% evidence |
| Exact sum: 24.4 + 11.8 + 15.9 + 3.2 = 55.3 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -11% and the one-year return is -4.2%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 5Keurig Dr Pepper Inc.this pageKDP | 50.5/100Mixed-positive evidence66% evidence | FADING | 14.4/35 Revenue 9.2% · PAT 21.8% · OPM change -3 pp 53% evidence | 9.8/25 ROCE 1.4% · OPM 19% 57% evidence | 14.2/20 P/E 19.5× · PEG 0.86 65% evidence | 12.1/20 RS sector 3% · RS bench -2.9% · 1Y -9.6%4 of 12 weeks ahead 100% evidence |
| Exact sum: 14.4 + 9.8 + 14.2 + 12.1 = 50.5 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 6Coca-Cola Consolidated, Inc.COKE | 47.9/100Thin evidence · provisional56% evidence | ASLEEP | 15.8/35 Revenue — · PAT — · OPM change -1.8 pp 39% evidence | 12.4/25 ROCE 6.5% · OPM 12.9% 76% evidence | 10.3/20 P/E 22.4× · PEG — 15% evidence | 9.4/20 RS sector 5.6% · RS bench -0.6% · 1Y 58.6%0 of 12 weeks ahead 100% evidence |
| Exact sum: 15.8 + 12.4 + 10.3 + 9.4 = 47.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 7Primo Brands CorporationPRMB | 47.1/100Thin evidence · provisional51% evidence | ASLEEP | 16.5/35 Revenue 18.6% · PAT — · OPM change -1 pp 40% evidence | 7.5/25 ROCE 1.5% · OPM 8.5% 57% evidence | 8.5/20 P/E 134.5× · PEG — 15% evidence | 14.6/20 RS sector 6.1% · RS bench 0% · 1Y -1.7%8 of 12 weeks ahead 100% evidence |
| Exact sum: 16.5 + 7.5 + 8.5 + 14.6 = 47.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 8Celsius Holdings, Inc.CELH | 42.3/100Mixed-negative evidence66% evidence | BASING | 23.1/35 Revenue 100% · PAT 56.8% · OPM change 2 pp 53% evidence | 10.2/25 ROCE 5% · OPM 17.8% 57% evidence | 6.1/20 P/E 82.5× · PEG 2.4 65% evidence | 2.9/20 RS sector -36.1% · RS bench -40% · 1Y -43.1%0 of 12 weeks ahead 100% evidence |
| Exact sum: 23.1 + 10.2 + 6.1 + 2.9 = 42.3 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -36.1% and the one-year return is -43.1%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 9National Beverage Corp.FIZZ | 33.1/100Adverse evidence81% evidence | ASLEEP | 8.3/35 Revenue -1.7% · PAT -2.7% · OPM change -1.4 pp 83% evidence | 14.0/25 ROCE 8% · OPM 16.9% 76% evidence | 6.5/20 P/E 17.4× · PEG 3.72 65% evidence | 4.3/20 RS sector -14.3% · RS bench -19.3% · 1Y -31.6%0 of 12 weeks ahead 100% evidence |
| Exact sum: 8.3 + 14 + 6.5 + 4.3 = 33.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Coca-Cola Europacific Partners PLCCCEP | 56.4/100Thin evidence · provisional38% evidence | TURNING | 18.0/35 Revenue — · PAT — · OPM change — 9% evidence | 10.7/25 ROCE 3.2% · OPM — 46% evidence | 11.2/20 P/E 18.1× · PEG — 15% evidence | 16.5/20 RS sector 6.8% · RS bench 0.6% · 1Y 12%2 of 12 weeks ahead 100% evidence |
| Exact sum: 18 + 10.7 + 11.2 + 16.5 = 56.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 11Suja Life, Inc.SUJA | 48.8/100Thin evidence · provisional14% evidence | ASLEEP | 17.1/35 Revenue — · PAT — · OPM change — 6% evidence | 11.7/25 ROCE 8.7% · OPM — 46% evidence | 10.0/20 P/E — · PEG — 0% evidence | 10.0/20 RS sector — · RS bench — · 1Y —0 of 1 week ahead 0% evidence |
| Exact sum: 17.1 + 11.7 + 10 + 10 = 48.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 12Buda Juice, Inc.BUDA | 41.4/100Thin evidence · provisional36% evidence | 11.5/35 Revenue 16.7% · PAT -25% · OPM change -10 pp 53% evidence | 10.8/25 ROCE 5.4% · OPM 16.9% 57% evidence | 9.1/20 P/E 42.4× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —0 of 11 weeks ahead 0% evidence | |
| Exact sum: 11.5 + 10.8 + 9.1 + 10 = 41.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 13Zevia PBCZVIA | 39.9/100Thin evidence · provisional42% evidence | BREAKING OUT | 20.6/35 Revenue 11.1% · PAT — · OPM change 11.7 pp 40% evidence | 5.4/25 ROCE -6.6% · OPM -5.1% 57% evidence | 10.0/20 P/E — · PEG — 0% evidence | 3.9/20 RS sector -15.6% · RS bench -20.4% · 1Y -47.7%9 of 12 weeks ahead 70% evidence |
| Exact sum: 20.6 + 5.4 + 10 + 3.9 = 39.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Keurig Dr Pepper Inc.'s stock price today?
Keurig Dr Pepper Inc. trades at $31.1, −6.7% over the past year. The company is valued at $42.0 B. The stock sits at 59% of its 52-week range of $25–$35, +8.5% versus its 200-day average. On the tape, the price is topping out, 16 weeks in. — as of 5 August 2026.
What were Keurig Dr Pepper Inc.'s latest quarterly results?
Keurig Dr Pepper Inc. reported revenue of $4.0 B and net profit of $0.3 B for the Mar 26 quarter. Revenue rose 9.6% and profit fell 48.1% year on year. Earnings per share were $0.20. The operating margin was 19.1%, 2.9 pp lower than a year earlier. — as of 5 August 2026.
What is Keurig Dr Pepper Inc.'s revenue?
Keurig Dr Pepper Inc. reported revenue of $4.0 B in the Mar 26 quarter, +9.6% year on year. For the full FY25 fiscal year, revenue was $16.6 B (+8.1%). Over the last 4 years revenue compounded at 7.0% a year. — as of 5 August 2026.
What is Keurig Dr Pepper Inc.'s profit?
Keurig Dr Pepper Inc. earned $0.3 B of net profit in the Mar 26 quarter, −48.1% year on year. Full-year FY25 profit was $2.1 B. The operating margin ran 19.1% in the latest quarter. — as of 5 August 2026.
What is Keurig Dr Pepper Inc.'s market cap?
Keurig Dr Pepper Inc.'s market capitalisation is $42.0 B at a stock price of $31.1. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 5 August 2026.
What is Keurig Dr Pepper Inc.'s P/E ratio?
Keurig Dr Pepper Inc. trades at a P/E of 23.1×, at the 43rd percentile of its own 4-year range, against a long-run median of 23.8×. This is a comparison with the stock's own history, not a value call — as of 5 August 2026.
Does Keurig Dr Pepper Inc. pay a dividend?
Yes — Keurig Dr Pepper Inc. declared $0.23 per share for Mar 26, and $0.92 per share across the last four reported quarters. The latest quarter is up 7.0% on the same quarter a year earlier. — as of 5 August 2026.
What is Keurig Dr Pepper Inc.'s dividend per share?
Keurig Dr Pepper Inc.'s most recently declared dividend is $0.23 per share for Mar 26, giving $0.92 per share over the trailing twelve months. Each figure is the amount declared for that quarter as reported, added across four quarters for the trailing total. — as of 5 August 2026.
What is Keurig Dr Pepper Inc.'s dividend yield?
Keurig Dr Pepper Inc.'s trailing dividend yield is 2.96%: $0.92 declared per share across the last four reported quarters, against a share price of $31.1. Each quarter’s figure is the amount declared for that quarter as reported, added across four quarters and divided by the latest close. — as of 5 August 2026.
Is Keurig Dr Pepper Inc. overvalued?
On its own history, Keurig Dr Pepper Inc. looks mid-range against its own history: its P/E of 23.1× sits at the 43rd percentile of its 4-year range (long-run median 23.8×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 5 August 2026.
Is Keurig Dr Pepper Inc. growing?
Not right now — Keurig Dr Pepper Inc.'s latest numbers are shrinking: latest-quarter revenue +9.6% year on year, profit −48.1%, and the margin −2.9 pp at 19.1%. The earnings engine currently reads: deteriorating — as of 5 August 2026.
How is Keurig Dr Pepper Inc. performing?
Keurig Dr Pepper Inc. is topping out, 16 weeks in. Its latest quarter's revenue rose 9.6% and profit fell 48.1% year on year. Against the S&P 500 it has been ahead on a trailing-13-week view for 2 weeks. This describes what the data did, not a rating. — as of 5 August 2026.
What stage is Keurig Dr Pepper Inc. in?
Improving — profit growth bottomed 3 quarters ago at −29.6% and has held its recovery at +20.4%, ROCE holding at 6.6%. The read comes from the last 12 quarters of growth (revenue growth +9.3% latest, profit growth +20.4% latest, eps growth +22.7% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 5 August 2026.
Is Keurig Dr Pepper Inc. in an uptrend?
It is stalling — the price is topping out (week 16 of stage 3), trading +8.5% versus its 200-day average and at 59% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 5 August 2026.
Is Keurig Dr Pepper Inc. beating the market?
On recent form, yes — Keurig Dr Pepper Inc. has been ahead of the S&P 500 on a trailing-13-week view for 2 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 8.1 years the stock moved +28% against the S&P 500's +176% — behind the index over the full window. — as of 5 August 2026.
Will Keurig Dr Pepper Inc.'s stock price go up?
This page publishes no price forecast for Keurig Dr Pepper Inc. What it measures instead: the stock price is $31.1, the price is topping out 16 weeks in. Its P/E of 23.1× sits at the 43rd percentile of its own 4-year range. — as of 5 August 2026.
Is the market betting against Keurig Dr Pepper Inc.?
Somewhat — short interest is 4.7% of Keurig Dr Pepper Inc.'s tradable float, about 3.6 days to cover at typical volumes. A moderate reading: some money is positioned against it. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 5 August 2026.
Does Keurig Dr Pepper Inc. have too much debt?
It is moderate — Keurig Dr Pepper Inc.'s debt-to-equity is 0.86. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. Read the returns on this page with that leverage in mind — as of 5 August 2026.
What is Keurig Dr Pepper Inc.'s capex?
Keurig Dr Pepper Inc. spent $1.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $0.5 B. — as of 5 August 2026.
What is Keurig Dr Pepper Inc.'s cash flow?
Keurig Dr Pepper Inc. generated $2.0 B of operating cash flow in FY25 and $1.5 B of free cash flow after $0.5 B of capital spending. Reported profit that year was $2.1 B, so operating cash ran behind profit. — as of 5 August 2026.
Is Keurig Dr Pepper Inc.'s profit real cash?
Yes — over the last 3 fiscal years, 97% of Keurig Dr Pepper Inc.'s reported profit arrived as operating cash. In FY25, operating cash was $2.0 B against reported profit of $2.1 B. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 5 August 2026.
How financially safe is Keurig Dr Pepper Inc.?
On the balance sheet, the Z-score reads 1.34 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That is inside the danger band — a real balance-sheet risk. — as of 5 August 2026.
Where is Keurig Dr Pepper Inc. in its business cycle?
Keurig Dr Pepper Inc.'s FY25 operating margin was 21.6%, against a 5-year band of 16.9%–22.8%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 19.1%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 5 August 2026.
What could break the Keurig Dr Pepper Inc. story?
The sharpest disagreement: annual EPS moved +45.7% against a −6.7% price move — the market has not yet caught up with the delivery. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 5 August 2026.
Is Keurig Dr Pepper Inc. a stock worth studying right now?
This is not investment advice. The machine read: Keurig Dr Pepper Inc.'s three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: whether the price catches up with earnings that have already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 5 August 2026.